Buy Semax 0.1%, 10 mg
€15.70
Semax 0.1%, 10 mg, is a formulation-dependent heptapeptide research reagent for analytical and in vitro laboratory work. Pharma Research .eu should provide verified active content, sequence, HPLC purity and LC-MS identity before European procurement.
Buy Semax 0.1%, 10 mg, for Advanced Laboratory Research in Europe
Semax is a synthetic seven-residue peptide commonly represented as H-Met-Glu-His-Phe-Pro-Gly-Pro-OH. A 0.1% presentation described as β10 mgβ requires precise formulation disclosure: if 10 mg is the total product mass at 0.1% w/w, the nominal Semax content is 0.01 mg; if 10 mg refers to active peptide, the total formulation mass would need to be 10 g for a true 0.1% w/w preparation. Pharma Research .eu should verify the basis, active content, solvent and packaging before publication.pubchem.ncbi.nlm.nih+1
Uncompromising Purity and Analytical Characterisation
Semax should be specified as the linear heptapeptide:
H-Met-Glu-His-Phe-Pro-Gly-Pro-OH
The free N-terminus and free C-terminal carboxylic acid should be stated explicitly. Semax acetate, N-acetyl Semax, Semax amidate and N-acetyl Semax amidate are different chemical forms with different molecular formulae, masses and analytical behaviour. They must not be combined under the generic name βSemaxβ.
The description βSemax 0.1%, 10 mgβ is ambiguous. It may describe a 10 mg total formulation, a 10 mg active-peptide quantity, a liquid concentration or a dry blend. A compliant product page should state:
-
Whether 0.1% is w/w, w/v or another concentration basis.
-
Whether 10 mg refers to active Semax or total product.
-
Total formulation mass or volume.
-
Solvent, buffer and excipients.
-
Active-content assay and batch uniformity.
-
Packaging configuration and physical state.
For the peptide fraction, the appropriate research-grade target is β₯99.0% purity by RP-HPLC, subject to confirmation by the actual batch certificate of analysis. Some recognised laboratory suppliers list Semax at β₯98% HPLC, so the product specification must reflect the actual validated release threshold rather than an assumed value.sigmaaldrich+1
A complete CoA should include:
-
RP-HPLC purity percentage and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Sequence and terminal-group designation.
-
Free-peptide or acetate-form information.
-
Active Semax content in the 0.1% formulation.
-
Total formulation mass or volume.
-
Excipients, solvent and preservative information.
-
Residual-solvent results from synthesis and purification.
-
Water or residual-moisture content where relevant.
-
Heavy-metal or elemental-impurity results where included.
-
Lot number, manufacture date, retest date and storage requirements.
The commonly reported free-peptide formula is CββHβ βNβOββS, with average molecular mass approximately 813.9β813.93 g/mol and exact mass near 813.3480 Da. Semax acetate is reported separately with formula CββHβ β NβOββS and molecular mass near 874.0 g/mol.pubchem.ncbi.nlm.nih+2
The physical appearance depends on the formulation. Neat Semax is generally a white to off-white lyophilised powder. A 0.1% preparation may be a clear or slightly opalescent liquid, powder blend or other matrix-dependent presentation. Appearance should be verified against the batch specification and cannot substitute for HPLC, mass spectrometry or active-content testing.
High purity and accurate active-content measurement are essential because methionine may undergo oxidation, and incomplete synthesis, terminal-group variants and residual reagents can generate closely related impurities. In a dilute 0.1% preparation, matrix effects and concentration errors may be proportionally important. Non-characterised material may be unsuitable for quantitative LC-MS, stability-indicating methods or reproducible in vitro studies.
Principal Laboratory Applications and Research Methodologies
Semax is suitable for controlled laboratory research involving ACTH-fragment peptide chemistry, analytical characterisation and in vitro neurobiological model development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
RP-HPLC and LC-MS method development. Semax can serve as a defined peptide analyte for retention-time assignment, intact-mass confirmation and impurity profiling. Methods should distinguish free Semax from acetate, acetylated, amidated or oxidised forms.
Dilute-formulation assay testing. A 0.1% formulation requires quantitative verification of active peptide content, homogeneity, recovery and matrix background. Laboratories may assess between-container uniformity, dilution accuracy, solvent compatibility and changes during storage.
Comparative stability research. Researchers may evaluate the influence of pH, light, temperature, oxidation and container material on Semax integrity. Methionine oxidation should be monitored by HPLC and mass spectrometry, while apparent concentration loss should be distinguished from adsorption or precipitation.
In vitro biochemical and cellular models. A verified preparation may be incorporated into controlled cell-free or cellular systems examining peptide-associated signalling or neurotrophic read-outs. Experimental plans should include vehicle and matrix controls, concentration confirmation and independent verification that the 0.1% formulation does not alter the assay endpoint.
If β10 mgβ means total formulation mass and 0.1% means w/w, the nominal Semax content is approximately 0.01 mg, or 10 Β΅g. If β10 mgβ means active Semax, the product is not a 0.1% w/w formulation unless the total preparation mass is 10 g. These alternatives must not be conflated in marketing or procurement documentation.
Using the free-peptide molecular mass of 813.9 g/mol, 0.01 mg corresponds to approximately 12.3 nmol, whereas 10 mg active Semax corresponds to approximately 12.3 Β΅mol. No molar concentration should be displayed until the formulation basis is confirmed.
Compound Stability, Optimal Storage, and Safe Handling Protocols
Dry Semax is commonly stored at approximately β20Β°C in a sealed, dry and light-protected container. A 0.1% liquid or matrix-based formulation requires separate stability data because solvent, pH, preservative, container and headspace may substantially affect integrity.nexyralab+1
Recommended controls include:
-
Store lyophilised Semax at β20Β°C unless the CoA specifies otherwise.
-
Store a liquid or diluted 0.1% formulation according to its formulation-specific CoA.
-
Protect the material from direct light, heat and unnecessary air exposure.
-
Keep containers tightly closed and minimise moisture ingress.
-
Allow sealed refrigerated or frozen containers to equilibrate before opening to reduce condensation.
-
Use low-binding materials where adsorption could affect recovery.
-
Prepare aliquots only where compatible with the documented formulation.
-
Store opened or prepared material at 2β8Β°C only when validated.
-
Avoid repeated freezeβthaw cycles.
-
Record concentration basis, active content, solvent, preparation date, operator and storage history.
Methionine oxidation is a relevant degradation pathway. In a dilute formulation, apparent loss may also arise from adsorption, evaporation, precipitation, non-uniform mixing or matrix interference. Stability should therefore be evaluated using active-content assay, RP-HPLC and LC-MS rather than visual appearance alone.
If the product is a dry formulation, reconstitution should follow a validated laboratory method. If it is supplied as a liquid 0.1% preparation, further dilution should occur only after confirming the matrix, pH, preservative profile and compatibility with the intended analytical or cellular workflow.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | Semax 0.1%, 10 mg nominal presentation |
| Identity requiring clarification | Whether 10 mg refers to active peptide or total formulation |
| Concentration basis | Confirm whether 0.1% is w/w, w/v or another basis |
| Common designation | Semax; ACTH(4β7)-Pro-Gly-Pro |
| Sequence | H-Met-Glu-His-Phe-Pro-Gly-Pro-OH |
| Residue count | 7 amino acids |
| IUPAC name | Full systematic peptide name should be confirmed on the CoA; sequence notation is preferred |
| CAS Registry Number | 80714-61-0 for commonly reported free Semax |
| Molecular formula, free peptide | CββHβ βNβOββS |
| Average molecular mass, free peptide | Approximately 813.9β813.93 g/mol |
| Physical state and colour | Lyophilised white to off-white solid or formulation-dependent clear liquid |
| Active-content example | If 10 mg total at 0.1% w/w: nominally 0.01 mg Semax |
| Solubility profile | Formulation-dependent; solvent and matrix compatibility require validation |
| Typical purity | Proposed target β₯99.0% by RP-HPLC for peptide fraction |
| Identity testing | LC-MS, ESI-MS or high-resolution MS |
| Long-term storage | Typically β20Β°C for dry peptide; follow formulation-specific CoA for liquid material |
Semax free peptide and Semax acetate must be specified separately because their formulae and molecular masses differ. The final product table should not present one as the other.pubchem.ncbi.nlm.nih+2
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position this Semax 0.1% presentation as a documented European laboratory reagent, provided the concentration basis and 10 mg quantity are resolved before publication. The product file should state active peptide content, total formulation mass or volume, solvent and excipients, batch-specific CoA, SDS, sequence, purity result, identity data and storage instructions.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
Whether 0.1% is w/w or w/v.
-
Whether 10 mg refers to active Semax or total product.
-
Free Semax versus Semax acetate or modified analogues.
-
Active-content assay and formulation uniformity.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Container-closure integrity and light protection.
-
Storage, transport and documentation requirements.
Until these details are confirmed, the item should be described as a Semax 0.1% research formulation with active content pending batch verification, rather than as a chemically complete 10 mg peptide product. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.